Sources

14 Total Sources

Novo Nordisk Loses $30.7 Billion After Ziltivekimab Fails Late-Stage Trial

Left43%

Center29%

Right29%

Novo Nordisk Market Value Drops $30 Billion After Ziltivekimab Drug Fails Study

Bloomberg20d ago

Novo's New Drug Fails in Closely Watched Heart, Stroke Study - Bloomberg

The Wall Street Journal20d ago

Novo Nordisk Stock Prices Drop as Ziltivekimab Fails to Reduce Heart Risk - WSJ

Novo Nordisk Shares Drop After Ziltivekimab Heart Drug Trial Fails

AD HOC NEWS20d ago

Novo Nordisk's Pipeline Setback Overshadows European and US Commercial Wins

Barron's20d ago

Novo Nordisk Stock Drops as Heart Drug Fails Late-Stage Trial - Barron's

Investopedia20d ago

Novo Nordisk Stock Sinks on Disappointing Heart Drug Trial Results

Stocktwits20d ago

NVO Stock Slumps After Late-Stage Trial Fails Primary Goal – Retail Says 'Current Revenue Drivers' Still Intact

streamlinefeed.co.ke20d ago

Novo Nordisk Plunges 10 Percent After Cardiovascular Drug Fails Trial | Streamline

Novo Nordisk's Ziltivekimab Fails to Reduce Major Heart Events in Phase 3 Trial

threads.com20d ago

A Novo Nordisk $NVO experimental drug called "ziltivekimab" failed to reduce the risk of heart attacks and strokes in a large study - Bloomberg

Facebook20d ago

Stock was down 9.5% after the company's experimental medicine ziltivekimab didn't achieve the expected risk reduction for major cardiovascular events.

StockTitan20d ago

Novo Nordisk ZEUS Trial: No MACE Benefit, HR 0.99 | NVO Stock News

MD Magazine20d ago

Ziltivekimab Fails to Reduce MACE Risk in Phase 3 ZEUS Trial | HCPLive